Decibel Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Decibel Therapeutics is a clinical-stage biotechnology company focused on developing treatments to restore and improve hearing and balance, addressing a significant unmet medical need. Based in Boston, Massachusetts, the company has built a proprietary platform that merges genomic insights with inner ear biology and gene-therapy expertise to identify and advance therapeutic candidates. Its lead program, DB-OTO, targets congenital, monogenic hearing loss, and the company also aims to regenerate inner ear hair cells to treat acquired hearing and balance disorders.

It serves patients affected by congenital and acquired hearing and balance conditions, with clinicians and researchers in those fields as its primary audience. In August 2023, the company launched its first global Phase I/II gene therapy trial, CHORD. The work sits within the biotechnology research industry, and Decibel operates as a small, research-focused company pursuing therapies for sensory disorders.

Get verified Decibel Therapeutics emails free

Company overview Employee directory